Selectively inhibiting c-RAF’s activity (kinase dependent and independent) represents a persistently attractive therapeutic approach in oncology, offering a high efficacy—low toxicity strategy to treating PDAC and other related RASMT—c-RAF driven malignancies (e.g., lung, colorectal, ovarian, urothelial, and skin cancer). This evidence concerns the gene RAF1 and skin cancer.